“We are particularly looking forward to increasing our business in India”

Emerging from the Institute of Cell Culture Technology at Bielefeld University, Germany, in 2009, Xell AG (formerly TeutoCell AG), has grown to become an independent and privately financed biotech company dedicated to cutting-edge innovation and developing expertise. With more than 20 years of hands-on experience in cell culture technology, Xell has drawn from its academic and technological knowledge to become a key partner in the design and distribution of cell culture solutions. The company is currently serving the Indian market through its partnership with Navi Mumbai-based Rane Rao Reshamia Laboratories. BioSpectrum interacted with Prof. Thomas Noll, Chairman, Supervisory Board, Xell AG, Germany to find out more about the company’s plans for 2021 and beyond. Edited excerpts;

- Dr Manbeena Chawla

What are Xell’s major offerings in terms of products and services for the life sciences industry?

Xell AG was founded back in 2009 as a spin-off from the Cell Culture Technology lab at Bielefeld University. Our goal was to make the lab’s proprietary technology – rational, lean-designed and chemically defined cell culture media (CD-CCM) – accessible to both the global biopharma industry and the biotech community. The Cell Culture Technology lab at Bielefeld University can even trace its experience and refinement of animal cell culture technology way back to 1989, a time when technologies were being developed to express proteins from mammalian cells economically.

Staying true to our origins, this particular scientific approach will always remain an inherent part of Xell’s DNA. Proof of this lies in our analytical capabilities, particularly the analysis of the spent media samples that we have continuously developed in parallel with the ever-increasing demand for CDCCM on the global market. This makes Xell the ideal partner for biopharma, biotechnological and feed and food companies.

For more than a decade now, our experience and industry-leading knowledge has allowed us to build an extensive, versatile and all-around superior product and service portfolio for any client or application utilising CHO, HEK, Hybridoma, BHK, MDCK, Vero or other human cell lines. We have established long-lasting client relationships with partners of varying sizes based all over the globe. What’s more, we are also represented by various agents and distributors who support our ambition to strategically increase our market share outside of Europe.

How was the FY20-21 for the company? What growth does Xell foresee in 2021?